In vitro and in vivo pre-clinical analysis of a Fab2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancersReport as inadecuate




In vitro and in vivo pre-clinical analysis of a Fab2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers - Download this document for free, or read online. Document in PDF available to download.

EJNMMI Research

, 1:1

First Online: 07 June 2011Received: 09 March 2011Accepted: 07 June 2011

Abstract

BackgroundThe objective of this study was to characterize the in vitro and in vivo properties of the Fab-2 fragment of panitumumab and to investigate its potential for imaging and radioimmunotherapy.

MethodsThe panitumumab Fab-2 was generated by enzymatic pepsin digestion. After the integrity and immunoreactivity of the Fab-2 was evaluated, the fragment was radiolabeled. In vivo studies included direct quantitation of tumor targeting and normal organ distribution of the radiolabeled panitumumab Fab-2 as well as planar γ-scintigraphy and PET imaging.

ResultsThe panitumumab Fab-2 was successfully produced by peptic digest. The Fab-2 was modified with the CHX-A-DTPA chelate and efficiently radiolabeled with either In or Y. In vivo tumor targeting was achieved with acceptable uptake of radioactivity in the normal organs. The tumor targeting was validated by both imaging modalities with good visualization of the tumor at 24 h.

ConclusionsThe panitumumab Fab-2 fragment is a promising candidate for imaging of HER1-positive cancers.

Electronic supplementary materialThe online version of this article doi:10.1186-2191-219X-1-1 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Karen J Wong - Kwamena E Baidoo - Tapan K Nayak - Kayhan Garmestani - Martin W Brechbiel - Diane E Milenic

Source: https://link.springer.com/







Related documents